Volume | 5,160,818 |
|
|||||
News | (2) | ||||||
Day High | 0.9458 | Low High |
|||||
Day Low | 0.893 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
bluebird bio Inc | BLUE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.9102 | 0.893 | 0.9458 | 0.9228 | 0.9125 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
9,762 | 5,160,818 | US$ 0.9193097 | US$ 4,744,390 | - | 0.879 - 5.53 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:48:17 | 1 | US$ 0.9399 | USD |
bluebird bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
100.59M | 109.34M | - | 3.6M | -266.58M | -2.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
bluebird bio News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BLUE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.95 | 1.05 | 0.8812 | 0.9580233 | 6,281,756 | -0.0101 | -1.06% |
1 Month | 1.29 | 1.30 | 0.8812 | 1.06 | 5,233,797 | -0.3501 | -27.14% |
3 Months | 1.00 | 1.92 | 0.879 | 1.27 | 8,370,130 | -0.0601 | -6.01% |
6 Months | 2.96 | 5.53 | 0.879 | 1.78 | 10,014,059 | -2.02 | -68.25% |
1 Year | 3.70 | 5.53 | 0.879 | 2.30 | 6,946,637 | -2.76 | -74.60% |
3 Years | 28.67 | 35.5883 | 0.879 | 4.97 | 4,821,916 | -27.73 | -96.72% |
5 Years | 139.00 | 147.48 | 0.879 | 12.63 | 3,336,662 | -138.06 | -99.32% |
bluebird bio Description
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. |